Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tectonic Therapeutic (TECX) Non-Current Deffered Revenue (2017 - 2022)

Tectonic Therapeutic (TECX) has 6 years of Non-Current Deffered Revenue data on record, last reported at $10000.0 in Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 88.89% to $10000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $10000.0, a 88.89% decrease, with the full-year FY2021 number at $30000.0, down 89.13% from a year prior.
  • Non-Current Deffered Revenue reached $10000.0 in Q3 2022 per TECX's latest filing, down from $12000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for TECX hit a ceiling of $781000.0 in Q2 2018 and a floor of $10000.0 in Q3 2022.
  • A 5-year average of $340722.2 and a median of $303500.0 in 2020 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 446.83% in 2018, then tumbled 92.0% in 2022.
  • Tracing TECX's Non-Current Deffered Revenue over 5 years: stood at $689000.0 in 2018, then plummeted by 68.94% to $214000.0 in 2019, then rose by 28.97% to $276000.0 in 2020, then tumbled by 89.13% to $30000.0 in 2021, then crashed by 66.67% to $10000.0 in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for TECX at $10000.0 in Q3 2022, $12000.0 in Q2 2022, and $30000.0 in Q1 2022.